PRPhilippe De La Rochere

Philippe De La Rochere

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Philippe De La Rochere has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A comprehensive analysis of humanized mouse models for the study of cancer immunotherapies

    by Philippe De La Rochere, Laure Loumagne, Melanie Rathaux, Marine Dubois, Fariba Nemati, Sophie Viel, Tamara Slavnic, Jayant Thatte, Qixiang Li Henry, Xuesong Ouyang, et al.

    Humanized immune system (HIS) mouse models, generated by engrafting tumors and hematopoietic cells of human (Hu) origin into immunodeficient host mice, effectively recapitulate key aspects of the crosstalk between human immune cells and tumors. These models represent a valuable tool for the preclinical evaluation of immunotherapies. In this study, we provide a comprehensive comparison of two widely used HIS models: the Hu-CD34+ model, which engrafts Hu-hematopoietic cells derived from Hu-CD34+ hematopoietic stem cells (HSCs), and the Hu-PBMC model, which utilizes Hu-peripheral blood mononuclear cells (PBMCs). We assess the kinetics, quality and extent of immune cell engraftment, as well as the development of graft-versus-host disease (GVHD). Additionally, we investigate the impact of different immunodeficient host mouse strains on immune cell reconstitution in the Hu-CD34+ model. Both HIS models were engrafted with human tumors derived from either cell lines or patient-derived xenografts (PDX), revealing distinct immune-tumor interactions that influenced antitumor responses. Notably, tumor responses to T-cell-directed therapies, including anti-PD1 antibodies, IL-2-anti-IL-2 antibody complexes, and T-cell engagers, varied across these models. Our findings provide novel insights into the properties and limitations of HIS models, offering a critical resource for optimizing next-generation immuno-oncology strategies and guiding the design of future therapeutic interventions.

  • Open Access

    Supplementary figures from IL2/Anti-IL2 Complex Combined with CTLA-4, But Not PD-1, Blockade Rescues Antitumor NK Cell Function by Regulatory T-cell Modulation

    by Pamela Caudana, Nicolas Gonzalo Núñez, Philippe De La Rochere, Anaïs Pinto, Jordan Denizeau, Ruby Alonso, Leticia Laura Niborski, Olivier Lantz, Christine Sedlik, Eliane Piaggio

  • Open Access

    Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer

    by Edith Borcoman, Philippe De La Rochere, Wilfrid Richer, Sophie Vacher, Walid Chemlali, Clémentine Krucker, Nanour Sirab, Francois Radvanyi, Yves Allory, Géraldine Pignot, et al.

    Although immune checkpoint inhibitors have shown improvement in survival in comparison to chemotherapy in urothelial bladder cancer, many patients still fail to respond to these treatments and actual efforts are made to identify predictive factors of response to immunotherapy. Understanding the tumor-intrinsic molecular basis, like oncogenic pathways conditioning the presence or absence of tumor-infiltrating T cells (TILs), should provide a new rationale for improved anti-tumor immune therapies. In this study, we found that urothelial bladder cancer from human samples bearing PIK3CA gene mutations was significantly associated with lower expression of a defined immune gene signature, compared to unmutated ones. We identified a reduced 10-gene immune gene signature that discriminates muscle-invasive bladder cancer (MIBC) samples according to immune infiltration and PIK3CA mutation. Using a humanized mouse model, we observed that BKM120, a pan-PI3K inhibitor, significantly inhibited the growth of a human bladder cancer cell line bearing a PIK3CA mutation, associated to increased immune cell infiltration (hCD45+). Using qRT-PCR, we also found an increase in the expression of chemokines and immune genes in PIK3CA-mutated tumors from mice treated with BKM120, reflecting an active immune infiltrate in comparison to untreated ones. Moreover, the addition of BKM120 rendered PIK3CA-mutated tumors sensitive to PD-1 blockade. Our results provide a relevant rationale for combination strategies of PI3K inhibitors with immune checkpoint inhibitors to overcome resistance to immune checkpoint inhibitors.


  • IL2/Anti-IL2 Complex Combined with CTLA-4, But Not PD-1, Blockade Rescues Antitumor NK Cell Function by Regulatory T-cell Modulation

    by Pamela Caudana, Nicolas Gonzalo Núñez, Philippe De La Rochere, Anaïs Pinto, Jordan Denizeau, Ruby Alonso, Leticia Laura Niborski, Olivier Lantz, Christine Sedlik, Eliane Piaggio

    High-dose IL2 immunotherapy can induce long-lasting cancer regression but is toxic and insufficiently efficacious. Improvements are obtained with IL2/anti-IL2 complexes (IL2Cx), which redirect IL2 action to CD8+ T and natural killer (NK) cells. Here, we evaluated the efficacy of combining IL2Cx with blockade of inhibitory immune pathways. In an autochthonous lung adenocarcinoma model, we show that the IL2Cx/anti–PD-1 combination increases CD8+ T-cell infiltration of the lung and controls tumor growth. In the B16-OVA model, which is resistant to checkpoint inhibition, combination of IL2Cx with PD-1 or CTLA-4 pathway blockade reverses that resistance. Both combinations work by reinvigorating exhausted intratumoral CD8+ T cells and by increasing the breadth of tumor-specific T-cell responses. However, only the IL2Cx/anti–CTLA-4 combination is able to rescue NK cell antitumor function by modulating intratumoral regulatory T cells. Overall, association of IL2Cx with PD-1 or CTLA-4 pathway blockade acts by different cellular mechanisms, paving the way for the rational design of combinatorial antitumor therapies.


  • Humanized Mice for the Study of Immuno-Oncology

    by Philippe De La Rochere, Silvia Guil-Luna, Didier Decaudin, Georges Azar, Sukhvinder S. Sidhu, Eliane Piaggio


  • Heparan sulfates targeting increases MHC class I- and MHC class II-restricted antigen presentation and CD8 + T-cell response

    by Delphine Knittel, Adeline Gadzinski, Stéphane Hua, Jordan Denizeau, Alexandra Savatier, Philippe de la Rochère, Jean-Claude Boulain, Sebastian Amigorena, Eliane Piaggio, Christine Sedlik, et al.


  • Effective antitumor therapy based on a novel antibody-drug conjugate targeting the Tn carbohydrate antigen

    by Christine Sedlik, Adèle Heitzmann, Sophie Viel, Rafik Ait Sarkouh, Cornélie Batisse, Frédéric Schmidt, Philippe De La Rochere, Nathalie Amzallag, Eduardo Osinaga, Pablo Oppezzo, et al.

    Antibody-drug conjugates (ADC), combining the specificity of tumor recognition by monoclonal antibodies (mAb) and the powerful cytotoxicity of anticancer drugs, are currently under growing interest and development. Here, we studied the potential of Chi-Tn, a mAb directed to a glyco-peptidic tumor-associated antigen, to be used as an ADC for cancer treatment. First, we demonstrated that Chi-Tn specifically targeted tumor cells in vivo. Also, using flow cytometry and deconvolution microscopy, we showed that the Chi-Tn mAb is rapidly internalized – condition necessary to ensure the delivery of conjugated cytotoxic drugs in an active form, and targeted to early and recycling endosomes. When conjugated to saporin (SAP) or to auristatin F, the Chi-Tn ADC exhibited effective cytotoxicity to Tn-positive tumor cells in vitro, which correlated with the level of tumoral Tn expression. Furthermore, the Chi-Tn mAb conjugated to auristatin F also exhibited efficient antitumor activity in vivo, validating for the first time the use of an anti-Tn antibody as an effective ADC.


  • Open Access

    Different immunogenicity but similar antitumor efficacy of two DNA vaccines coding for an antigen secreted in different membrane vesicle‐associated forms

    by Christine Sedlik, James Vigneron, Lea Torrieri‐Dramard, Fabien Pitoiset, Jordan Denizeau, Caroline Chesneau, Philippe de la Rochere, Olivier Lantz, Clotilde Thery, Bertrand Bellier

    The induction of an active immune response to control or eliminate tumours is still an unfulfilled challenge. We focused on plasmid DNA vaccines using an innovative approach whereby the antigen is expressed in association with extracellular vesicles (EVs) to facilitate antigen cross‐presentation and improve induced immunity. Our two groups had independently shown previously that DNA vaccines encoding EV‐associated antigens are more efficient at inducing cytotoxic T‐cell responses than vaccines encoding the non‐EV‐associated antigen. Here, we compared our two approaches to associate the ovalbumin (OVA) antigen to EVs: (a) by fusion to the lipid‐binding domain C1C2 of MFGE8(=lactadherin), which is exposed on the surface of secreted membrane vesicles; and (b) by fusion to retroviral Gag capsid protein, which is incorporated inside membrane‐enclosed virus‐like particles. Plasmids encoding either form of modified OVA were used as DNA‐based vaccines (i.e. injected into mice to allow in vivo expression of the antigen associated to EVs). We show that both DNA vaccines induced, with similar efficiency, OVA‐specific CD8+ T cells and total IgG antibodies. By contrast, each vaccine preferentially stimulated different isotypes of immunoglobulins, and the OVA‐C1C2‐encoding vaccine favoured antigen‐specific CD4+ T lymphocyte induction as compared to the Gag‐OVA vaccine. Nevertheless, both OVA‐C1C2 and Gag‐OVA vaccines efficiently prevented in vivo outgrowth of OVA‐expressing tumours and reduced tumour progression when administered to tumour‐bearing mice, although with variable efficacies depending on the tumour models. DNA vaccines encoding EV‐associated antigens are thus promising immunotherapy tools in cancer but also potentially other diseases.


  • Open Access

    Age-related changes in human hematopoietic stem/progenitor cells

    by Klaudia Kuranda, Jacques Vargaftig, Philippe de la Rochere, Christine Dosquet, Dominique Charron, Florence Bardin, Cecile Tonnelle, Dominique Bonnet, Michele Goodhardt

    Adult stem cells are critical for maintaining cellular homeostasis throughout life, yet the effects of age on their regenerative capacity are poorly understood. All lymphoid and myeloid blood cell lineages are continuously generated from hematopoietic stem cells present in human bone marrow. With age, significant changes in the function and composition of mature blood cells are observed. In this study, we report that age-related changes also occur in the human hematopoietic stem cell compartment. We find that the proportion of multipotent CD34+CD38− cells increases in the bone marrow of elderly (>70 years) individuals. CD34+CD38+CD90−CD45RA+/−CD10− and CD34+CD33+ myeloid progenitors persist at the same level in the bone marrow, while the frequency of early CD34+CD38+CD90−CD45RA+CD10+ and committed CD34+CD19+ B-lymphoid progenitors decreases with age. In contrast to mice models of aging, transplantation experiments with immunodeficient NOD/SCID/IL-2Rγ null (NSG) mice showed that the frequency of NSG repopulating cells does not change significantly with age, and there is a decrease in myeloid lineage reconstitution. An age-related decrease in the capacity of CD34+ cells to generate myeloid cells was also seen in colony-forming assays in vitro. Thus, with increasing age, human hematopoietic stem/progenitor cells undergo quantitative changes as well as functional modifications.